Cytovia Therapeutics develops Flex-NK™ bispecific antibodies and TALEN® gene-edited CAR-iNK cells to enhance the activation and targeting of natural killer (NK) cells at tumor sites. This approach aims to improve cancer immunotherapy outcomes and address significant gaps in cancer prevention and treatment.
Funding
$45M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer immunotherapies often struggle to effectively target and activate natural killer (NK) cells within the tumor microenvironment, limiting their ability to eradicate cancer cells. Existing treatments may also lack the specificity needed to distinguish between cancerous and healthy cells, leading to off-target effects and reduced efficacy.
Solution
Cytovia Therapeutics is developing a suite of immune-therapeutic agents designed to enhance the activation and targeting of NK cells directly at tumor sites. Their Flex-NK™ bispecific antibodies are engineered to redirect and activate NK cells, improving their ability to recognize and eliminate cancer cells. Cytovia is also advancing TALEN® gene-edited CAR-iNK cells, which are designed to provide enhanced tumor-specific targeting and improved persistence compared to conventional NK cell therapies. These approaches aim to overcome limitations of current immunotherapies by increasing the precision and potency of NK cell-mediated cancer cell killing.
Target Audience
The primary target audience includes patients with solid tumors and hematological malignancies who are not responsive to existing therapies, as well as oncologists and hematologists seeking more effective and targeted immunotherapeutic options.
Features
- Flex-NK™ bispecific antibodies that bind to both NK cells and tumor-associated antigens, facilitating targeted NK cell activation
- TALEN® gene-editing technology to create CAR-iNK cells with enhanced specificity and anti-tumor activity
- CAR-iNK cells engineered for improved persistence and reduced off-target effects
- Targeting of tumor-specific antigens such as GPC3